The benefit-risk balance for the use of lopinavir-ritonavir in COVID-19 needs to be monitored on an ongoing basis, therefore a systematic benefit-risk assessment was designed and conducted. A key objective of this study was to provide a platform for a dynamic systematic benefit-risk evaluation...
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 来自 Semantic Scholar 喜欢 0 阅读量: 87 作者:X-T Ye,Y-L Luo,S-C Xia,Q-F Sun,L Hong 摘要: Objective: The Coronavirus disease 2019 (COVID-19) which outbroke in December 2019 is highly contagious with ...
No control armSevere COVID-19: (O2sat <94%, PaO2: FiO2<300) (Treatment naïve)NRClinical improvement in 68%, Extubation 57%, Discharge 47%57% on MV and 8% on ECMO23% (LFT abnormality 23%, 8% discontinued)13%No virologic data, no control arm, significant clinical improvement ...
The Solidarity Trial was established by the WHO in March to find an effective COVID-19 treatment for hospitalized patients. It was originally designed to have five trial arms, including standard or usual care provided to COVID-19 patients, remdesivir, lopinavir/ritonavir combined, lopinavir/ritonavi...
COVID-19, cytokines, inflammation, and spices: How are they related? Ajaikumar B. Kunnumakkara, ... Bharat B. Aggarwal, in Life Sciences, 2021 6.4 Lopinavir/Ritonavir Lopinavir a protease inhibitor prescribed for the treatment of HIV. The oral bioavailability of lopinavir is considerabl...
Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID–19? Nader Tavakoli Shahla Chaichian Abolfazl Mehdizadehkashi BMC Pregnancy and Childbirth(2023) ...
A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase... A therapeutic agent that targets both viral replication and the hyper-reactive immune response would offer a highly desirable treatment for se...
tocilizumabThree patients diagnosed with severe COVID pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received ...
To date, there are no data on bradycardia related to LPV/RTV treatment for COVID-19 critical ill patients. The aim of this prospective preliminary study was to record the risk of bradycardia for COVID-19 patients treated with LPV/RTV.Christophe Beyls...
Systematic reviewMeta-analysisObjective:To systematically evaluate the efficacy and safety of lopinavir/ritonavir(LPV/r)in the treatment of COVID-19.Methods:PubMed,Embase,Ovid,CNKI,CBM,Wanfang,and VIP databases were searched to obtain the clinical studies of LPV/r in the treatment of COVID-19 ...